About Pro-Dex (NASDAQ:PDEX)
Pro-Dex, Inc. (Pro-Dex) designs and produces surgical and dental instruments and motion control products used in the medical, factory automation and scientific research industries. The Company operates through four segments: Pro-Dex, OMS, Fineline and Engineering Services Division (ESD). The Pro-Dex segment provides primarily medical and dental instruments using shared production and assembly machines and workforce. The OMS segment is engaged in providing multi-axis motion control applications. The Fineline segment manufactures plastic injection molds for various industries. The ESD segment provides permanent placement and contract services in the fields of engineering, manufacturing and quality to diverse businesses. In addition to Pro-Dex, the names Micro Motors and Oregon Micro Systems are used for marketing purposes as brand names. It provides engineering consulting services, as well as quality and regulatory consulting services, to a range of industries through EDS.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PDEX
CUSIPN/A
Phone949-769-3200
Debt
Debt-to-Equity RatioN/A
Current Ratio7.07%
Quick Ratio5.45%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$21.94 million
Price / Sales1.36
Cash Flow$1.3645 per share
Price / Cash5.02
Book Value$3.42 per share
Price / Book2.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$5.08 million
Net Margins11.23%
Return on Equity16.04%
Return on Assets13.93%
Miscellaneous
Employees76
Outstanding Shares4,360,000
Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions
What is Pro-Dex's stock symbol?
Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."
How were Pro-Dex's earnings last quarter?
Pro-Dex, Inc. (NASDAQ:PDEX) announced its quarterly earnings data on Tuesday, February, 10th. The medical instruments supplier reported ($0.05) earnings per share (EPS) for the quarter. The medical instruments supplier had revenue of $2.80 million for the quarter, compared to analysts' expectations of $2.60 million. Pro-Dex had a net margin of 11.23% and a return on equity of 16.04%. View Pro-Dex's Earnings History.
What price target have analysts set for PDEX?
1 equities research analysts have issued twelve-month price targets for Pro-Dex's shares. Their predictions range from $9.00 to $9.00. On average, they expect Pro-Dex's stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Pro-Dex.
Who are some of Pro-Dex's key competitors?
Some companies that are related to Pro-Dex include Neovasc (NVCN), Arch Therapeutics (ARTH), Presbia (LENS), Cellect Biotechnology (APOP), Interpace Diagnostics Gr (IDXG), AIT Therapeutics (AITB), Cytori Therapeutics (CYTX), InVivo Therapeutics (NVIV), Valeritas (VLRX), Alliqua BioMedical (ALQA), Neurometrix (NURO), Amedica (AMDA), Avinger (AVGR), STRATA Skin Sciences (SSKN), TearLab (TEAR) and Lombard Medical Technologies (EVARF).
Who are Pro-Dex's key executives?
Pro-Dex's management team includes the folowing people:
- Nicholas John Swenson, Independent Chairman of the Board (Age 48)
- Richard L. Van Kirk Jr., President, Chief Executive Officer, Chief Operating Officer, Director (Age 56)
- Alisha K. Charlton, Chief Financial Officer (Age 47)
- Raymond E. Cabillot, Independent Director (Age 53)
- William J. Farrell III, Independent Director (Age 43)
- David C. Hovda, Independent Director (Age 54)
Has Pro-Dex been receiving favorable news coverage?
Headlines about PDEX stock have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pro-Dex earned a media sentiment score of 0.17 on Accern's scale. They also gave media headlines about the medical instruments supplier an impact score of 46.23 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Pro-Dex?
Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pro-Dex's stock price today?
One share of PDEX stock can currently be purchased for approximately $6.85.
How big of a company is Pro-Dex?
Pro-Dex has a market capitalization of $29.98 million and generates $21.94 million in revenue each year. Pro-Dex employs 76 workers across the globe.
How can I contact Pro-Dex?
Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3200 or via email at [email protected]
MarketBeat Community Rating for Pro-Dex (PDEX)
MarketBeat's community ratings are surveys of what our community members think about Pro-Dex and other stocks. Vote "Outperform" if you believe PDEX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDEX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pro-Dex (NASDAQ:PDEX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Pro-Dex in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 31.39%. The high price target for PDEX is $9.00 and the low price target for PDEX is $9.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $9.00 | $9.00 | $9.00 | $9.00 |
| Price Target Upside: | 31.39% upside | 20.00% upside | 20.00% upside | 20.00% upside |
Pro-Dex (NASDAQ:PDEX) Consensus Price Target History
Pro-Dex (NASDAQ:PDEX) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Pro-Dex (NASDAQ:PDEX) Earnings History and Estimates Chart
Pro-Dex (NASDAQ PDEX) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/11/2017 | Q3 2017 | | $0.17 | | $6.62 million | View | N/A |  |
| 2/9/2017 | Q2 2017 | | $0.77 | | $4.60 million | View | N/A | |
| 9/15/2016 | Q4 2016 | | $0.05 | | $5.29 million | View | N/A | |
| 5/12/2016 | Q3 2016 | | $0.08 | | $5.34 million | View | N/A | |
| 2/11/2016 | Q2 2016 | | $0.09 | | $5.44 million | View | N/A | |
| 11/10/2015 | Q1 2016 | | ($0.03) | | $4.10 million | View | N/A | |
| 9/17/2015 | Q4 2015 | | $0.02 | | $4.07 million | View | N/A | |
| 5/14/2015 | Q3 2015 | | ($0.02) | | $3.92 million | View | N/A | |
| 2/10/2015 | Q215 | | ($0.05) | $2.60 million | $2.80 million | View | N/A | |
| 11/13/2014 | Q115 | | ($0.04) | $2.55 million | $2.60 million | View | N/A | |
| 9/18/2014 | Q4 14 | | $0.01 | | $3.20 million | View | N/A | |
| 5/12/2014 | Q3 2014 | | ($0.11) | | $2.40 million | View | N/A | |
| 2/6/2014 | Q4 | | ($0.10) | | $2.64 million | View | N/A | |
| 11/13/2013 | Q114 | | $0.06 | $3.50 million | $2.60 million | View | N/A | |
| 9/25/2013 | Q413 | | ($0.20) | $3.70 million | $2.70 million | View | N/A | |
| 5/13/2013 | Q3 2013 | | ($0.23) | | $3.06 million | View | N/A | |
| 1/10/2013 | Q2 2013 | | ($0.11) | | | View | N/A | |
| 10/25/2012 | Q1 2013 | | ($0.02) | | | View | N/A | |
| 9/4/2012 | Q4 2012 | | ($0.14) | | | View | N/A | |
| 5/4/2012 | Q3 2012 | | ($0.16) | | | View | N/A | |
| 2/6/2012 | Q2 2012 | | ($0.09) | | | View | N/A | |
| 11/9/2011 | Q1 2012 | | $0.14 | | | View | N/A | |
| 9/14/2011 | Q4 2011 | | $0.31 | | | View | N/A | |
| 5/10/2011 | Q3 2011 | | $0.26 | | | View | N/A | |
| 2/10/2011 | Q2 2011 | | $0.12 | | | View | N/A | |
| 11/9/2010 | Q1 2011 | | $0.10 | | | View | N/A | |
| 9/28/2010 | Q4 2010 | | ($1.20) | | | View | N/A | |
| 4/29/2010 | Q3 2010 | | $0.05 | | | View | N/A | |
| 2/4/2010 | Q2 2010 | | $0.18 | | | View | N/A | |
| 10/29/2009 | Q1 2010 | | $0.06 | | | View | N/A | |
| 9/17/2009 | Q4 2009 | | $0.06 | | | View | N/A | |
| 5/14/2009 | Q3 2009 | | ($0.62) | | | View | N/A | |
| 2/12/2009 | Q2 2009 | | $0.02 | | | View | N/A | |
| 11/13/2008 | Q1 2009 | | ($0.04) | | | View | N/A | |
| 9/18/2008 | Q4 2008 | | ($0.12) | | | View | N/A | |
| 5/15/2008 | Q3 2008 | | $0.03 | | | View | N/A | |
| 2/14/2008 | Q2 2008 | | $0.09 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Pro-Dex (NASDAQ:PDEX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Pro-Dex (NASDAQ PDEX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 40.70%
Institutional Ownership Percentage: 5.91%
Pro-Dex (NASDAQ PDEX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/12/2018 | William James Farrell III | Director | Buy | 2,200 | $6.75 | $14,850.00 | | |
| 5/18/2017 | Kirk Richard Lee Van Jr | CEO | Sell | 940 | $5.75 | $5,405.00 | 18,760 | |
| 3/23/2016 | William James Farrell III | Director | Buy | 600 | $3.42 | $2,052.00 | 1,700 | |
| 3/2/2016 | Nicholas John Swenson | Director | Buy | 1,281 | $3.15 | $4,035.15 | 75,388 | |
| 3/1/2016 | Nicholas John Swenson | Director | Buy | 17,821 | $3.15 | $56,136.15 | 75,388 | |
| 1/15/2016 | Raymond E Cabillot | Director | Buy | 14,913 | $2.25 | $33,554.25 | | |
| 1/14/2016 | Nicholas John Swenson | Director | Buy | 7,353 | $2.30 | $16,911.90 | 55,974 | |
| 9/15/2015 | Nicholas John Swenson | Director | Buy | 22,537 | $2.30 | $51,835.10 | 47,588 | |
| 8/21/2015 | Nicholas John Swenson | Director | Buy | 4,020 | $2.28 | $9,165.60 | 14,341 | |
| 7/20/2015 | Raymond E Cabillot | Director | Buy | 1,700 | $2.30 | $3,910.00 | | |
| 5/28/2015 | Kirk Richard Lee Van Jr | CEO | Buy | 5,100 | $2.32 | $11,832.00 | | |
| 4/30/2014 | Harold A Hurwitz | CEO | Buy | 2,203 | $1.90 | $4,185.70 | | |
| 4/30/2014 | Nicholas John Swenson | Director | Buy | 317,231 | $1.90 | $602,738.90 | | |
| 8/29/2013 | Raymond E Cabillot | Director | Buy | 10,500 | $1.90 | $19,950.00 | | |
| 8/19/2013 | Nicholas John Swenson | Director | Buy | 5,702 | $1.90 | $10,833.80 | | |
| 7/12/2013 | Nicholas John Swenson | Director | Buy | 5,545 | $1.90 | $10,535.50 | | |
| 7/3/2013 | Nicholas John Swenson | Director | Buy | 5,000 | $1.90 | $9,500.00 | | |
| 6/25/2013 | Nicholas John Swenson | Director | Buy | 5,373 | $1.90 | $10,208.70 | | |
| 6/19/2013 | Raymond E Cabillot | Director | Buy | 1,279 | $1.90 | $2,430.10 | | |
| 6/11/2013 | Nicholas John Swenson | Director | Buy | 4,950 | $1.90 | $9,405.00 | | |
| 6/3/2013 | Nicholas John Swenson | Director | Buy | 12,303 | $1.90 | $23,375.70 | | |
| 5/24/2013 | Raymond E Cabillot | Director | Buy | 8,312 | $1.90 | $15,792.80 | | |
| 5/21/2013 | Nicholas John Swenson | Director | Buy | 3,510 | $1.90 | $6,669.00 | | |
| 5/14/2013 | Raymond E Cabillot | Director | Buy | 25,119 | $1.99 | $49,986.81 | | |
| 5/7/2013 | Nicholas John Swenson | Director | Buy | 28,206 | $2.00 | $56,412.00 | | |
| 4/30/2013 | Raymond E Cabillot | Director | Buy | 5,176 | $2.00 | $10,352.00 | | |
| 4/17/2013 | Nicholas John Swenson | Major Shareholder | Buy | 12,859 | $2.00 | $25,718.00 | | |
| 4/16/2013 | Raymond E Cabillot | Director | Buy | 12,758 | $2.00 | $25,516.00 | | |
| 4/9/2013 | Nicholas John Swenson | Major Shareholder | Buy | 2,293 | $2.00 | $4,586.00 | | |
| 4/9/2013 | Raymond E Cabillot | Director | Buy | 2,294 | $2.00 | $4,588.00 | | |
| 3/8/2013 | Raymond E Cabillot | Director | Buy | 25,560 | $2.00 | $51,120.00 | | |
| 11/19/2012 | Nicholas John Swenson | Major Shareholder | Buy | 9,884 | $1.97 | $19,471.48 | | |
| 10/25/2012 | Nicholas John Swenson | Major Shareholder | Buy | 1,485 | $1.87 | $2,776.95 | | |
| 10/18/2012 | Nicholas John Swenson | Major Shareholder | Buy | 29,442 | $1.90 | $55,939.80 | | |
| 10/5/2012 | Nicholas John Swenson | Major Shareholder | Buy | 6,743 | $1.89 | $12,744.27 | | |
| 10/1/2012 | Nicholas John Swenson | Major Shareholder | Buy | 2,384 | $1.80 | $4,291.20 | | |
(Data available from 1/1/2013 forward)
Pro-Dex (NASDAQ PDEX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Pro-Dex Inc (PDEX) Director Buys $14,850.00 in Stock
www.americanbankingnews.com - February 13 at 6:46 PM |
 | Rick Van Kirk, CEO of Pro-Dex, Inc. Returns to “Stock Day” with Everett Jolly
finance.yahoo.com - February 12 at 9:03 AM |
| Pro-Dex, Inc. Announces Fiscal 2018 Second Quarter and Six-Month Results
finance.yahoo.com - February 8 at 4:26 PM |
| Pro-Dex (PDEX) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - January 31 at 3:04 AM |
| Uptick Newswire “Stock Day” Interviews CEO of Pro-Dex on its 2017 Accomplishments in the Medical Industry
finance.yahoo.com - December 21 at 10:17 AM |
| ETFs with exposure to Pro-Dex, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 4:35 PM |
| Pro-Dex, Inc. :PDEX-US: Earnings Analysis: Q1, 2018 By the Numbers : December 18, 2017
finance.yahoo.com - December 18 at 4:36 PM |
| Pro-Dex, Inc. Announces Top Workplace Recognition, Best Scientific Medical Product Award and Placement as a Fastest-Growing Orange County Company
finance.yahoo.com - December 12 at 4:56 PM |
| Pro-Dex, Inc. Announces Fiscal 2018 First Quarter Results
finance.yahoo.com - November 12 at 11:31 AM |
| ETFs with exposure to Pro-Dex, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 8:34 AM |
| ETFs with exposure to Pro-Dex, Inc. : October 26, 2017
finance.yahoo.com - October 27 at 9:29 AM |
| Should You Buy Pro-Dex Inc (PDEX) At $7.2?
finance.yahoo.com - October 3 at 10:30 AM |
| ETFs with exposure to Pro-Dex, Inc. : October 2, 2017
finance.yahoo.com - October 3 at 10:30 AM |
| Pro-Dex, Inc. :PDEX-US: Earnings Analysis: Q4, 2017 By the Numbers : September 25, 2017
finance.yahoo.com - September 25 at 10:52 AM |
| ETFs with exposure to Pro-Dex, Inc. : September 19, 2017
finance.yahoo.com - September 20 at 7:35 AM |
| ETFs with exposure to Pro-Dex, Inc. : September 19, 2017
finance.yahoo.com - September 20 at 7:35 AM |
| Pro-Dex, Inc. :PDEX-US: Earnings Analysis: 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 19 at 6:27 AM |
| Pro-Dex's (PDEX) "Buy" Rating Reiterated at Ascendiant Capital Markets
www.americanbankingnews.com - September 9 at 11:58 AM |
| Pro-Dex, Inc. Announces Fiscal 2017 Fourth Quarter and Full-Year Results
finance.yahoo.com - September 5 at 5:10 PM |
| Pro-Dex CEO Overviews with Uptick Network on Company Progression in its Technologies and Customer Relations
finance.yahoo.com - August 18 at 7:01 AM |
| PRO DEX INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - September 14 at 6:49 PM |
| PRO DEX INC Files SEC form 8-K, Other Events
biz.yahoo.com - April 19 at 5:05 PM |
| PRO DEX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - January 8 at 12:58 PM |
| PRO DEX INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - December 7 at 3:06 PM |
| PRO DEX INC Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - November 10 at 4:06 PM |
| PRO DEX INC Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 10 at 4:04 PM |
| PRO DEX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
biz.yahoo.com - September 14 at 4:02 PM |
| PRO DEX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition
biz.yahoo.com - May 13 at 4:07 PM |
Pro-Dex (NASDAQ:PDEX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Pro-Dex (NASDAQ:PDEX) Income Statement, Balance Sheet and Cash Flow Statement
Pro-Dex (NASDAQ PDEX) Stock Chart for Sunday, April, 22, 2018
Loading chart…
